Interventions for improving adherence to ocular hypotensive therapy (Q24241641)

1

0 references

Robert Harper

object named as

Robert Harper

4

0 references

David Henson

object named as

David Henson

3

0 references

author name string

Lois C Orton

Cochrane Database of Systematic Reviews

2

0 references

publication date

15 April 2009

0 references

published in

0 references

cites work

Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Once-daily versus twice-daily levobunolol (0.5%) therapy. A crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Fixed-dose combinations improve medication compliance: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Validation of a questionnaire for comparing the tolerability of ophthalmic medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Accuracy of an electronic monitoring and reminder device for use with travoprost eye drops

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Medical versus surgical interventions for open angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Chronic open angle glaucoma: patient awareness of the nature of the disease, topical medication, compliance and the prevalence of systemic symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Publication bias in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Glaucoma patients not compliant with their drug therapy: clinical and behavioural aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Learning to live with glaucoma: a qualitative study of diagnosis and the impact of sight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Interventions for enhancing medication adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Microprocessor controlled compliance monitor for eye drop medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Compliance, adherence, and concordance: implications for asthma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Outpatient process quality evaluation and the Hawthorne Effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Is patient satisfaction sensitive to changes in the quality of care? An exploitation of the Hawthorne effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Development of the 25-item National Eye Institute Visual Function Questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

An observational study of antibiotic prescribing behavior and the Hawthorne effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Resisting medicines: a synthesis of qualitative studies of medicine taking

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Number of people with glaucoma worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

The number of people with glaucoma worldwide in 2010 and 2020

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Patient persistency with topical ocular hypotensive therapy in a managed care population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Patient compliance in hypertension: role of illness perceptions and treatment beliefs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Improved compliance measures: applications in an ambulatory hypertensive drug trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Self-reported adherence to cholesterol-lowering medication in patients with familial hypercholesterolaemia: the role of illness perceptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Evaluation of quality of life for patients with glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Risk factors for progressive visual field loss in primary open angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Compliance Barriers in Glaucoma: A Systematic Classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

The patient's perspective: adherence or non-adherence to asthma controller therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Patient adherence to medical treatment: a review of reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Medical interventions for primary open angle glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

From compliance to concordance: barriers to accomplishing a re-framed model of health care interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Glaucoma treatment with once-daily levobunolol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Compliance with topical pilocarpine treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Determinants of poor adherence in hypertensive patients: development and validation of the "Maastricht Utrecht Adherence in Hypertension (MUAH)-questionnaire"

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Compliance with topical timolol treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Dorzolamide versus pilocarpine as adjunctive therapies to timolol: a comparison of patient preference and impact on daily life

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Compliance with timolol treatment in glaucoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Quality of life in patients with early, moderate and advanced glaucoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

The Revised Illness Perception Questionnaire (IPQ-R)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Medication adherence in rheumatoid arthritis: effects of psychosocial factors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased intraocular pressure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

The effect of a glaucoma medication reminder cap on patient compliance and intraocular pressure.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glauc

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Comparative study of aqueous and oily pilocarpine in the production of ocular hypotension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Improving medication compliance: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Comparison of efficacy and tolerability between two gel-forming timolol maleate ophthalmic solutions in patients with glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Effect of changing medication regimens in glaucoma patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

A cross-over trial comparing once daily levobunolol with once and twice daily timolol.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

Self-reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006132.PUB2

7 January 2021

10.1002/14651858.CD006132.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

19370627

1 reference

Consolidated OpenCitations Corpus – April 2017